Vanucizumab 是一种首创的双特异性 IgG1 单克隆抗体，可同时阻断VEGF-A和血管生成素-2 (Ang-2) 与其受体相互作用。 Vanucizumab 具有抗血管生成和抗癌作用。
| 生物活性 | Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocksVEGF-Aandangiopoietin-2 (Ang-2)from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects[1]. |
体内研究
(In Vivo) | Vanucizumab (20mg /kg;i.p。每周1次;6周) 显示肿瘤生长抑制和诱导肿瘤停滞[2]。
| Animal Model: | SCID beige mice bearing Colo205 cells[2] | | Dosage: | 20 mg/kg | | Administration: | i.p.; once weekly; for 6 weeks | | Result: | Showed tumor growth inhibition. |
|
| CAS 号 | |
| 中文名称 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
